Kanpiduo (Indapamide, Candesartan Cilexetil)

Indapamide acts as a thiazide‑like diuretic, blocking sodium‑chloride reabsorption in the distal tubule, which promotes water loss and reduces fluid volume. Candesartan cilexetil is converted to candesartan, an angiotensin II type‑1 receptor blocker that prevents vasoconstriction and aldosterone release. Together they lower vascular resistance and blood volume, resulting in reduced arterial pressure.

The appropriate dose of Kanpiduo is determined by the prescribing healthcare professional based on the individual’s clinical condition, blood pressure response, and any concomitant therapies. Patients should follow the exact dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for Kanpiduo in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Kanpiduo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Kanpiduo combines a thiazide‑like diuretic with an angiotensin‑II receptor blocker, offering complementary mechanisms that can achieve better blood‑pressure control than monotherapy in many patients. Compared with single‑agent ACE inhibitors or ARBs, the addition of indapamide may reduce the need for separate diuretic prescriptions, while maintaining a safety profile comparable to other combination products.

Kanpiduo tablets should be stored at room temperature, below 25 °C, in their original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight. Keep the medication out of reach of children and do not use it after the expiration date printed on the packaging.

Kanpiduo is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse reactions to watch for include severe dehydration, hyperkalemia (high potassium levels), and angioedema, which can cause swelling of the face, lips, tongue or throat and may be life‑threatening. If any of these symptoms occur, seek immediate medical attention.

Kanpiduo is contraindicated in patients with known hypersensitivity to indapamide, candesartan, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, hyperkalemia, or those taking potassium‑sparing diuretics or other ARBs without close medical supervision.